Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

Executive Summary

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

You may also be interested in...



Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

Merck & Co. Strengthening Its Strong Position In Immuno-Oncology

Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.

Scrip's Rough Guide To IDO

IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel